{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T08:55:19Z","timestamp":1792054519609,"version":"4.4.0"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2007,8,3]],"date-time":"2007-08-03T00:00:00Z","timestamp":1186099200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BMC Musculoskelet Disord"],"published-print":{"date-parts":[[2007,12]]},"DOI":"10.1186\/1471-2474-8-73","type":"journal-article","created":{"date-parts":[[2007,8,3]],"date-time":"2007-08-03T18:13:29Z","timestamp":1186164809000},"source":"Crossref","is-referenced-by-count":81,"title":["Cyclo-oxygenase-2 selective inhibitors and nonsteroidal anti-inflammatory drugs: balancing gastrointestinal and cardiovascular risk"],"prefix":"10.1186","volume":"8","author":[{"given":"R Andrew","family":"Moore","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheena","family":"Derry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry J","family":"McQuay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2007,8,3]]},"reference":[{"key":"350_CR1","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.ejpain.2005.06.009","volume":"10","author":"H Breivik","year":"2006","unstructured":"Breivik H, Collett B, Ventafridda V, Cohen R, Gallacher D: Survey of chronic pain in Europe: Prevalence, impact on daily life, and treatment. Eur J Pain. 2006, 10: 287-333. 10.1016\/j.ejpain.2005.06.009.","journal-title":"Eur J Pain"},{"key":"350_CR2","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1016\/S0895-4356(00)00204-3","volume":"53","author":"MA Sprangers","year":"2000","unstructured":"Sprangers MA, de Regt EB, Andries F, van Agt HM, Bijl RV, de Boer JB, Foets M, Hoeymans N, Jacobs AE, Kempen GI, Miedema HS, Tijhuis MA, de Haes HC: Which chronic conditions are associated with better or poorer quality of life?. J Clin Epidemiol. 2000, 53: 895-907. 10.1016\/S0895-4356(00)00204-3.","journal-title":"J Clin Epidemiol"},{"key":"350_CR3","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1136\/ard.2003.017236","volume":"63","author":"C Miceli-Richard","year":"2004","unstructured":"Miceli-Richard C, Le Bars M, Schmidely N, Dougados M: Paracetamol in osteoarthritis of the knee. Ann Rheum Dis. 2004, 63: 923-930. 10.1136\/ard.2003.017236.","journal-title":"Ann Rheum Dis"},{"key":"350_CR4","doi-asserted-by":"publisher","first-page":"R1046","DOI":"10.1186\/ar1782","volume":"7","author":"RA Moore","year":"2005","unstructured":"Moore RA, McQuay HJ: Prevalence of opioid adverse events in chronic non-malignant pain: systematic review of randomised trials of oral opioids. Arthritis Res Ther. 2005, 7: R1046-1051. 10.1186\/ar1782.","journal-title":"Arthritis Res Ther"},{"key":"350_CR5","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1001\/archinte.160.14.2093","volume":"160","author":"S Hern\u00e1ndez-Diaz","year":"2000","unstructured":"Hern\u00e1ndez-Diaz S, Garc\u00eda Rodriguez LA: Association between nonsteroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding and perforation: An overview of epidemiological studies published in the 1990s. Arch Intern Med. 2000, 160: 2093-2099. 10.1001\/archinte.160.14.2093.","journal-title":"Arch Intern Med"},{"key":"350_CR6","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1056\/NEJM199209103271101","volume":"327","author":"MC Allison","year":"1992","unstructured":"Allison MC, Howatson AG, Torrance CJ, Lee FD, Russell RI: Gastrointestinal damage associated with the use of nonsteroidal antiinflammatory drugs. N Engl J Med. 1992, 327: 749-754.","journal-title":"N Engl J Med"},{"key":"350_CR7","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1053\/gast.1997.v112.pm9041228","volume":"112","author":"A Lanas","year":"1997","unstructured":"Lanas A, Serrano P, Bajador E, Esteva F, Benito R, Sainz R: Evidence of aspirin use in both upper and lower gastrointestinal perforation. Gastroenterology. 1997, 112: 683-689. 10.1053\/gast.1997.v112.pm9041228.","journal-title":"Gastroenterology"},{"key":"350_CR8","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/S1542-3565(04)00619-6","volume":"3","author":"JL Goldstein","year":"2005","unstructured":"Goldstein JL, Eisen GM, Lewis B, Gralnek IM, Zlotnick S, Fort JG: Video capsule endoscopy to prospectively assess small bowel injury with celecoxib, naproxen plus omeprazole, and placebo. Clin Gastroenterol Hepatol. 2005, 3: 133-141. 10.1016\/S1542-3565(04)00619-6.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"350_CR9","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1046\/j.1365-2125.1997.00631.x","volume":"44","author":"D Henry","year":"1997","unstructured":"Henry D, Page J, Whyte I, Nanra R, Hall C: Consumption of non-steroidal anti-inflammatory drugs and the development of functional renal impairment in elderly subjects. Results of a case-control study. Br J Clin Pharmacol. 1997, 44: 85-90. 10.1046\/j.1365-2125.1997.00631.x.","journal-title":"Br J Clin Pharmacol"},{"key":"350_CR10","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1093\/oxfordjournals.aje.a010234","volume":"151","author":"MR Griffin","year":"2000","unstructured":"Griffin MR, Yared A, Ray WA: Nonsteroidal antiinflamatory drugs and acute renal failure in elderly persons. Am J Epidemiol. 2000, 151: 488-496.","journal-title":"Am J Epidemiol"},{"key":"350_CR11","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1001\/archinte.160.6.777","volume":"160","author":"J Page","year":"2000","unstructured":"Page J, Henry D: Consumption of NSAIDs and the development of congestive heart failure in elderly patients: An underrecognized public health problem. Arch Intern Med. 2000, 160: 777-784. 10.1001\/archinte.160.6.777.","journal-title":"Arch Intern Med"},{"key":"350_CR12","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1097\/00001648-200303000-00020","volume":"14","author":"LA Garcia Rodriguez","year":"2003","unstructured":"Garcia Rodriguez LA, Hernandez-Diaz S: Non-steroidal anti-inflammatory drugs as a trigger of clinical heart failure. Epidemiology. 2003, 14: 240-246. 10.1097\/00001648-200303000-00020.","journal-title":"Epidemiology"},{"key":"350_CR13","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1056\/NEJM200011233432103","volume":"343","author":"C Bombardier","year":"2000","unstructured":"Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, Day R, Ferraz MB, Hawkey CJ, Hochberg MC, VIGOR Study Group: Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med. 2000, 343: 1520-1528. 10.1056\/NEJM200011233432103.","journal-title":"N Engl J Med"},{"key":"350_CR14","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1001\/jama.284.10.1247","volume":"284","author":"FE Silverstein","year":"2000","unstructured":"Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, Makuch R, Eisen G, Agrawal NM, Stenson WF, Burr AM, Zhao WW, Kent JD, Lefkowith JB, Verburg KM, Geis GS: Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. JAMA. 2000, 284: 1247-1255. 10.1001\/jama.284.10.1247.","journal-title":"JAMA"},{"key":"350_CR15","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/S0140-6736(04)16893-1","volume":"364","author":"TJ Schnitzer","year":"2004","unstructured":"Schnitzer TJ, Burmester GR, Mysler E, Hochberg MC, Doherty M, Ehrsam E, Gitton X, Krammer G, Mellein B, Matchaba P, TARGET Study Group: Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial. Lancet. 2004, 364: 665-674. 10.1016\/S0140-6736(04)16893-1.","journal-title":"Lancet"},{"key":"350_CR16","doi-asserted-by":"publisher","first-page":"2179","DOI":"10.1016\/S0140-6736(99)05388-X","volume":"353","author":"DW Taylor","year":"1999","unstructured":"Taylor DW, Barnett HJ, Haynes RB, Ferguson GG, Sackett DL, Thorpe KE, Simard D, Silver FL, Hachinski V, Clagett GP, Barnes R, Spence JD: Low-dose and high-dose acetylsalicylic acid for patients undergoing carotid endarterectomy: a randomised controlled trial. ASA and Carotid Endarterectomy (ACE) Trial Collaborators. Lancet. 1999, 353: 2179-2184. 10.1016\/S0140-6736(99)05388-X.","journal-title":"Lancet"},{"key":"350_CR17","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1056\/NEJMoa021735","volume":"348","author":"JA Baron","year":"2003","unstructured":"Baron JA, Cole BF, Sandler RS, Haile RW, Ahnen D, Bresalier R, McKeown-Eyssen G, Summers RW, Rothstein R, Burke CA, Snover DC, Church TR, Allen JI, Beach M, Beck GJ, Bond JH, Byers T, Greenberg ER, Mandel JS, Marcon N, Mott LA, Pearson L, Saibil F, van Stolk RU: A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med. 2003, 348: 891-899. 10.1056\/NEJMoa021735.","journal-title":"N Engl J Med"},{"key":"350_CR18","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1136\/bmj.332.7553.1302","volume":"332","author":"PM Kearney","year":"2006","unstructured":"Kearney PM, Baigent C, Godwin J, Halls H, Emberson JR, Patrono: Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ. 2006, 332: 1302-1308. 10.1136\/bmj.332.7553.1302.","journal-title":"BMJ"},{"key":"350_CR19","first-page":"S406","volume":"52","author":"LS Simon","year":"2005","unstructured":"Simon LS, White WB, MacDonald TM, Pan S, Rosenstein RB, Gaffney M: Cardiovascular safety of celecoxib: A meta-analysis of 41 clinical studies in 44,300 patients. Arth Rheum. 2005, 52: S406-","journal-title":"Arth Rheum"},{"key":"350_CR20","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1016\/j.clinthera.2005.07.019","volume":"27","author":"P Matchaba","year":"2005","unstructured":"Matchaba P, Gitton X, Krammer G, Ehrsam E, Sloan VS, Olson M, Mellein B, Hoexter G, Orloff J, Garaud JJ: Cardiovascular safety of lumiracoxib: A meta-analysis of all randomized controlled trials >\/=1 week and up to 1 year in duration of patients with osteoarthritis and rheumatoid arthritis. Clin Ther. 2005, 27: 1196-1214. 10.1016\/j.clinthera.2005.07.019.","journal-title":"Clin Ther"},{"key":"350_CR21","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1111\/j.1742-7843.2006.pto_302.x","volume":"98","author":"S Hern\u00e1ndez-Diaz","year":"2006","unstructured":"Hern\u00e1ndez-Diaz S, Varas-Lorenzo C, Garc\u00eda Rodr\u00edguez LA: Non-steroidal anti-inflammatory drugs and the risk of acute myocardial infarction. Basic Clin Pharmacol Toxicol. 2006, 98: 266-274. 10.1111\/j.1742-7843.2006.pto_302.x.","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"350_CR22","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/S0140-6736(04)16894-3","volume":"364","author":"ME Farkouh","year":"2004","unstructured":"Farkouh ME, Kirshner H, Harrington RA, Ruland S, Verheugt FW, Schnitzer TJ, Burmester GR, Mysler E, Hochberg MC, Doherty M, Ehrsam E, Gitton X, Krammer G, Mellein B, Gimona A, Matchaba P, Hawkey CJ, Chesebro JH, TARGET Study Group: : Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial. Lancet. 2004, 364: 675-84. 10.1016\/S0140-6736(04)16894-3.","journal-title":"Lancet"},{"key":"350_CR23","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1016\/S0140-6736(06)69666-9","volume":"368","author":"CP Cannon","year":"2006","unstructured":"Cannon CP, Curtis SP, FitzGerald GA, Krum H, Kaur A, Reicin AS, Bombardier C, Weinblatt ME, van der Heijde D, Erdmann E, Kaine L, for the MEDAL Steering Committee: Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) program: a randomised comparison. Lancet. 2006, 368: 1771-1781. 10.1016\/S0140-6736(06)69666-9.","journal-title":"Lancet"},{"key":"350_CR24","first-page":"355","volume":"31","author":"F Wolfe","year":"2004","unstructured":"Wolfe F, Michaud K, Burke TA, Zhao SZ: Longer use of COX-2-specific inhibitors compared to nonspecific nonsteroidal antiinflammatory drugs: a longitudinal study of 3639 patients in community practice. J Rheumatol. 2004, 31: 355-358.","journal-title":"J Rheumatol"},{"key":"350_CR25","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1136\/bmj.308.6921.81","volume":"308","author":"Collaboration Antiplatelet Trialists'","year":"1994","unstructured":"Antiplatelet Trialists' Collaboration: Collaborative overview of randomised trials of antiplatelet therapy, I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ. 1994, 308: 81-106.","journal-title":"BMJ"},{"key":"350_CR26","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1111\/j.1742-1241.2001.tb11025.x","volume":"55","author":"M Clarke","year":"2001","unstructured":"Clarke M, Halsey J: DICE 2: a further investigation of the effects of chance in life, death and subgroup analyses. Int J Clin Pract. 2001, 55: 240-242.","journal-title":"Int J Clin Pract"},{"key":"350_CR27","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1038\/sj.npp.1300690","volume":"30","author":"LJ Thal","year":"2005","unstructured":"Thal LJ, Ferris SH, Kirby L, Block GA, Lines CR, Yuen E, Assaid C, Nessly ML, Norman BA, Baranak CC, Reines SA, Rofecoxib Protocol 078 study group: A randomized, double-blind, study of rofecoxib in patients with mild cognitive impairment. Neuropsychopharmacol. 2005, 30: 1204-1215. 10.1038\/sj.npp.1300690.","journal-title":"Neuropsychopharmacol"},{"key":"350_CR28","doi-asserted-by":"publisher","first-page":"R644","DOI":"10.1186\/ar1704","volume":"7","author":"RA Moore","year":"2005","unstructured":"Moore RA, Derry S, Makinson GT, McQuay HJ: Tolerability and adverse events in clinical trials of celecoxib in osteoarthritis and rheumatoid arthritis: systematic review and meta-analysis of information from clinical trial reports. Arthritis Res Ther. 2005, 7: R644-R665. 10.1186\/ar1704.","journal-title":"Arthritis Res Ther"},{"key":"350_CR29","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1185\/030079905X43686","volume":"21","author":"DA Ramey","year":"2005","unstructured":"Ramey DA, Watson DJ, Yu C, Bolognese JA, Curtis SP, Reicin AS: The incidence of upper gastrointestinal adverse events in clinical trials of etoricoxib vs. non-selective NSAIDs: an updated combined analysis. Curr Med Res Opin. 2005, 21: 715-722. 10.1185\/030079905X43686.","journal-title":"Curr Med Res Opin"},{"key":"350_CR30","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1111\/j.1365-2036.2004.02118.x","volume":"20","author":"JL Goldstein","year":"2004","unstructured":"Goldstein JL, Eisen GM, Agrawal N, Stenson WF, Kent JD, Verburg KM: Reduced incidence of upper gastrointestinal ulcer complications with the COX-2 selective inhibitor, valdecoxib. Aliment Pharmacol Ther. 2004, 20: 527-538. 10.1111\/j.1365-2036.2004.02118.x.","journal-title":"Aliment Pharmacol Ther"},{"key":"350_CR31","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1185\/030079904X3078","volume":"20","author":"DJ Watson","year":"2004","unstructured":"Watson DJ, Yo Q, Bpolognese JA, Reicin AS, Simon TJ: The upper gastrointestinal safety of rofecoxib vs. NSAIDs: an updated combined analysis. Curr Med Res Opin. 2004, 20: 1539-1548. 10.1185\/030079904X3078.","journal-title":"Curr Med Res Opin"},{"key":"350_CR32","doi-asserted-by":"publisher","first-page":"2280","DOI":"10.1161\/hc4401.100078","volume":"104","author":"MA Konstam","year":"2001","unstructured":"Konstam MA, Weir MR, Reicin A, Shapiro D, Sperling RS, Barr E, Gertz BJ: Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib. Circulation. 2001, 104: 2280-2288.","journal-title":"Circulation"},{"key":"350_CR33","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1097\/01.mjt.0000127360.23508.04","volume":"11","author":"WB White","year":"2004","unstructured":"White WB, Strand V, Roberts R, Whelton A: Effects of the cyclooxygenase-2 specific inhibitor valdecoxib versus nonsteroidal anti-inflammatory agents and placebo on cardiovascular thrombotic events in patients with arthritis. Am J Ther. 2004, 11: 244-250. 10.1097\/01.mjt.0000127360.23508.04.","journal-title":"Am J Ther"},{"issue":"Suppl 9","key":"350_CR34","first-page":"1600","volume":"48","author":"S Curtis","year":"2003","unstructured":"Curtis S, Mukhopadhyay S, Ramey D, Reicin A: Cardiovascular safety summary associated with the etoricoxib development program. Arthritis Rheum. 2003, 48 (Suppl 9): 1600-","journal-title":"Arthritis Rheum"},{"key":"350_CR35","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1136\/bmj.325.7365.624","volume":"325","author":"M Mamdani","year":"2002","unstructured":"Mamdani M, Rochon PA, Juurlink DN, Kopp A, Anderson GM, Naglie G, Austin PC, Laupacis A: Observational study of upper gastrointestinal haemorrhage in elderly patients given selective cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs. BMJ. 2002, 325: 624-10.1136\/bmj.325.7365.624.","journal-title":"BMJ"},{"key":"350_CR36","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1136\/gut.52.9.1265","volume":"52","author":"TM MacDonald","year":"2003","unstructured":"MacDonald TM, Morant SV, Goldstein JL, Burke TA, Pettitt D: Channelling bias and the incidence of gastrointestinal haemorrhage in users of meloxicam, coxibs, and older, non-specific non-steroidal anti-inflammatory drugs. Gut. 2003, 52: 1265-1270. 10.1136\/gut.52.9.1265.","journal-title":"Gut"},{"key":"350_CR37","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1016\/S0140-6736(02)11131-7","volume":"360","author":"WA Ray","year":"2002","unstructured":"Ray WA, Stein CM, Daughtery JR, Hall K, Arbogast PG, Griffin MR: Cox-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease. Lancet. 2002, 360: 1071-1073. 10.1016\/S0140-6736(02)11131-7.","journal-title":"Lancet"},{"key":"350_CR38","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1001\/archinte.163.4.481","volume":"163","author":"M Mamdani","year":"2003","unstructured":"Mamdani M, Rochon P, Juurlink DN, Anderson GM, Kopp A, Naglie G, Austin PC, Laupacis A: Effect of selective cyclooxygenase 2 inhibitors and naproxen on short-term risk of acute myocardial infarction in the elderly. Arch Intern Med. 2003, 163: 481-486. 10.1001\/archinte.163.4.481.","journal-title":"Arch Intern Med"},{"key":"350_CR39","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/S0140-6736(07)60234-7","volume":"369","author":"L Laine","year":"2007","unstructured":"Laine L, Curtis SP, Cryer B, Kaur A, Cannon CP, MEDAL Steering Committee: Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet. 2007, 369: 465-473. 10.1016\/S0140-6736(07)60234-7.","journal-title":"Lancet"},{"key":"350_CR40","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1016\/S0197-2456(97)00024-X","volume":"18","author":"MD Flather","year":"1997","unstructured":"Flather MD, Farkouh ME, Pogue JM, Yusuf S: Strengths and limitations of meta-analysis: larger studies may be more reliable. Control Clin Trial. 1997, 18: 568-579. 10.1016\/S0197-2456(97)00024-X.","journal-title":"Control Clin Trial"},{"key":"350_CR41","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/0197-2456(93)90003-V","volume":"14","author":"JJ Shuster","year":"1993","unstructured":"Shuster JJ: Fixing the number of events in large comparative trials with low event rates: a binomial approach. Control Clin Trial. 1993, 14: 198-208. 10.1016\/0197-2456(93)90003-V.","journal-title":"Control Clin Trial"},{"key":"350_CR42","first-page":"48","volume":"25","author":"G Rose","year":"1991","unstructured":"Rose G: Environmental health: problems and prospects. J Roy Coll Phys Lond. 1991, 25: 48-52.","journal-title":"J Roy Coll Phys Lond"},{"key":"350_CR43","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1053\/j.gastro.2005.10.002","volume":"130","author":"S Fries","year":"2006","unstructured":"Fries S, Grosser T, Price TS, Lawson JA, Kapoor S, DeMarco S, Pletcher MT, Wiltshire T, FitzGerald GA: Marked interindividual variability in the response to selective inhibitors of cyclooxygenase-2. Gastroenterol. 2006, 130: 55-64. 10.1053\/j.gastro.2005.10.002.","journal-title":"Gastroenterol"},{"key":"350_CR44","doi-asserted-by":"publisher","first-page":"2947","DOI":"10.1001\/jama.286.23.2947","volume":"286","author":"K Kroenke","year":"2001","unstructured":"Kroenke K, West SL, Swindle R, Gilsenan A, Eckert GJ, Dolor R, Stang P, Zhou XH, Hays R, Weinberger M: Similar effectiveness of paroxetine, fluoxetine, and sertraline in primary care: a randomized trial. JAMA. 2001, 286: 2947-2955. 10.1001\/jama.286.23.2947.","journal-title":"JAMA"},{"key":"350_CR45","doi-asserted-by":"publisher","first-page":"3003","DOI":"10.1001\/jama.286.23.3003","volume":"286","author":"G Simon","year":"2001","unstructured":"Simon G: Choosing a first line antidepressant. Equal on average does not mean equal for everyone. JAMA. 2001, 286: 3003-3004. 10.1001\/jama.286.23.3003.","journal-title":"JAMA"},{"key":"350_CR46","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/S0304-3959(98)00140-7","volume":"78","author":"RA Moore","year":"1998","unstructured":"Moore RA, Gavaghan D, Tramer MR, Collins SL, McQuay HJ: Size is everything\u2013large amounts of information are needed to overcome random effects in estimating direction and magnitude of treatment effects. Pain. 1998, 78: 209-216. 10.1016\/S0304-3959(98)00140-7.","journal-title":"Pain"},{"key":"350_CR47","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.1136\/bmj.309.6970.1677","volume":"309","author":"CE Counsell","year":"1994","unstructured":"Counsell CE, Clarke MJ, Slattery J, Sandercock PA: The miracle of DICE therapy for acute stroke: fact or fictional product of subgroup analysis?. BMJ. 1994, 309: 1677-1681.","journal-title":"BMJ"},{"issue":"Suppl 4","key":"350_CR48","doi-asserted-by":"publisher","first-page":"S7","DOI":"10.1186\/ar1793","volume":"7","author":"DA Peura","year":"2005","unstructured":"Peura DA, Goldkind L: Balancing the gastrointestinal benefits and risks of nonselective NSAIDs. Arth Res Ther. 2005, 7 (Suppl 4): S7-S13. 10.1186\/ar1793.","journal-title":"Arth Res Ther"},{"key":"350_CR49","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1053\/gast.2002.36013","volume":"123","author":"L Laine","year":"2002","unstructured":"Laine L, Bombardier C, Hawkey CJ, Davis B, Shapiro D, Brett C, Reicin A: Stratifying the risk of NSAID-related upper gastrointestinal clinical events: results of a double-blind outcomes study in patients with rheumatoid arthritis. Gastroenterol. 2002, 123: 1006-1012. 10.1053\/gast.2002.36013.","journal-title":"Gastroenterol"},{"key":"350_CR50","doi-asserted-by":"publisher","first-page":"1950","DOI":"10.1161\/CIRCULATIONAHA.105.602425","volume":"113","author":"F Andersohn","year":"2006","unstructured":"Andersohn F, Suissa S, Garbe E: Use of first- and second-generation cyclooxygenase-2-selective nonsteroidal anti-inflammatory drugs and risk of acute myocardial infarction. Circulation. 2006, 113: 1950-1957. 10.1161\/CIRCULATIONAHA.105.602425.","journal-title":"Circulation"},{"key":"350_CR51","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/1471-2474-7-79","volume":"7","author":"RA Moore","year":"2006","unstructured":"Moore RA, Derry S, Phillips CJ, McQuay HJ: Nonsteroidal anti-inflammatory drugs (NSAIDs), cyxlooxygenase-2 selective inhibitors (coxibs) and gastrointestinal harm: review of clinical trials and clinical practice. BMC Musculoskelet Disord. 2006, 7: 79-10.1186\/1471-2474-7-79.","journal-title":"BMC Musculoskelet Disord"},{"key":"350_CR52","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1046\/j.1365-2036.2003.01795.x","volume":"18","author":"MC Sturkenboom","year":"2003","unstructured":"Sturkenboom MC, Burke TA, Tangelder MJ, Dieleman JP, Walton S, Goldstein JL: Adherence to proton pump inhibitors or H2-receptor antagonists during the use of non-steroidal anti-inflammatory drugs. Aliment Pharmacol Ther. 2003, 18: 1137-1147. 10.1046\/j.1365-2036.2003.01795.x.","journal-title":"Aliment Pharmacol Ther"},{"key":"350_CR53","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/S0304-3959(99)00267-5","volume":"85","author":"MR Tramer","year":"2000","unstructured":"Tramer MR, Moore RA, Reynolds DJ, McQuay HJ: Quantitative estimation of rare adverse events which follow a biological progression: a new model applied to chronic NSAID use. Pain. 2000, 85: 169-182. 10.1016\/S0304-3959(99)00267-5.","journal-title":"Pain"},{"key":"350_CR54","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1111\/j.1440-1746.2004.03441.x","volume":"20","author":"MS Khuroo","year":"2005","unstructured":"Khuroo MS, Khuroo MS, Farahat KL, Kagevi IE: Treatment with proton pump inhibitors in acute non-variceal upper gastrointestinal bleeding: a meta-analysis. J Gastroenterol Hepatol. 2005, 20: 11-25. 10.1111\/j.1440-1746.2004.03441.x.","journal-title":"J Gastroenterol Hepatol"},{"key":"350_CR55","doi-asserted-by":"publisher","first-page":"16","DOI":"10.3109\/00365529609094726","volume":"218","author":"JJ Kolkman","year":"1996","unstructured":"Kolkman JJ, Meuwissen SG: A review on treatment of bleeding peptic ulcer: a collaborative task of gastroenterologist and surgeon. Scand J Gastroenterol Suppl. 1996, 218: 16-25.","journal-title":"Scand J Gastroenterol Suppl"},{"key":"350_CR56","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1016\/j.amjsurg.2005.07.019","volume":"190","author":"GA Sarosi Jr","year":"2005","unstructured":"Sarosi GA, Jaiswal KR, Nwariaku FE, Asolati M, Fleming JB, Anthony T: Surgical therapy of peptic ulcers in the 21st century: more common than you think. Am J Surg. 2005, 190: 775-779. 10.1016\/j.amjsurg.2005.07.019.","journal-title":"Am J Surg"}],"container-title":["BMC Musculoskeletal Disorders"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2474-8-73.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2474-8-73\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2474-8-73","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,17]],"date-time":"2024-02-17T07:26:11Z","timestamp":1708154771000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmcmusculoskeletdisord.biomedcentral.com\/articles\/10.1186\/1471-2474-8-73"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,8,3]]},"references-count":56,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2007,12]]}},"alternative-id":["350"],"URL":"https:\/\/doi.org\/10.1186\/1471-2474-8-73","relation":{},"ISSN":["1471-2474"],"issn-type":[{"value":"1471-2474","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,8,3]]},"article-number":"73"}}